<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811493/" ref="ordinalpos=4421&amp;ncbi_uid=2491436&amp;link_uid=PMC2811493" image-link="/pmc/articles/PMC2811493/figure/F5/" class="imagepopup">Figure 5. Models for regulation of bone turnover by leptin and IL-17A.  From: A Bone-Protective Role for IL-17 Receptor <span class="highlight" style="background-color:">Signaling</span> in Ovariectomy-Induced Bone Loss. </a></div><br /><div class="p4l_captionBody">A. Signaling via IL-17A and IL-17F promote mesenchymal stem cells (MSC) to undergo osteoblastogenesis and simulataneously inhibit adipogenesis Thus, the absence of IL-17RA may limit osteoblast development and drive accelerated bone turnover during OVX. B. Leptin can limit osteogenesis through a central pathway from the hypothalamus. By inhibiting leptin expression, IL-17 may aid in limiting bone turnover during OVX. In IL-17RAKO mice, bone loss is thus enhanced.</div></div>